Urania Therapeutics

An example of combining venture capital and capabilities in kind for drug development

NovAliX engages in drug discovery alliances with biotechnology companies and we make available our expertise in medicinal chemistry, biology and biophysical technologies through risk-sharing or in-kind contributions.

Urania Therapeutics, a “protein repair” company, aims to treat genetic diseases caused by nonsense mutations that lead to premature termination of protein synthesis. Their strategy is to use structure-based drug design to develop “readthrough” compounds to restore the synthesis of an entire protein and its physiological function.

This disruptive approach is supported by venture capital from Advent France Biotechnology (AFB) and Cap Innov’Est (CIE) and an in-kind contribution from NovAliX.

Full press release

Would you like more information?

We are ready to support your projects

This website uses cookies to improve user experience